Prospective, open-label, non-randomized, single-arm, dose titration study to investigate the efficacy and safety of IncobotulinumtoxinA in children deemed to require a total body dose up to 22U/kg (maximum dose 550U) during the study period for the treatment of upper and lower limb spasticity due to cerebral palsy
Latest Information Update: 29 Apr 2022
Price :
$35 *
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscle spasticity
- Focus Therapeutic Use
- Acronyms INCIPIT
- 28 Jul 2021 Status changed to recruiting.
- 04 Dec 2020 New trial record